Celgene Corp. (CELG)

95.55
0.81 0.84
NASDAQ : Health Technology
Prev Close 96.36
Open 95.95
Day Low/High 95.37 / 96.27
52 Wk Low/High 58.59 / 97.07
Volume 2.52M
Avg Volume 8.73M
Exchange NASDAQ
Shares Outstanding 705.26M
Market Cap 67.88B
EPS 5.70
P/E Ratio 14.69
Div & Yield N.A. (N.A)

Latest News

Jim Cramer: My Bet's on the 'Ladies' in This Year's Draft

Jim Cramer: My Bet's on the 'Ladies' in This Year's Draft

Analyzing this year's stock draft contest and individual stock-picking vs. indexing.

Keep Your Eye on the Oncology Sector Among Biotech Stocks

Keep Your Eye on the Oncology Sector Among Biotech Stocks

The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.

Seattle Genetics Struggles as Other Biotech Stocks Rise

Market is pretty much where it has been all day, nicely positive across the board. Biotech up nearly 2% on the day. Gilead Sciences, Inc. , and Celgene Corp. , are two large caps on the move for reasons we covered in previous posts. The Bristol-Myer...

A Solid Start for the Market

We are currently in process of restoring my access that is blocking me from seeing or commenting on the Daily Diary. We hope to have the problem resolved soon. Our apologies while getting the issue resolved. The market is off to a solid start this F...

Future Brightens for 2 Small Biotech Stocks

Future Brightens for 2 Small Biotech Stocks

The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.

I Like the Long Side of Bristol-Myers Squibb

I Like the Long Side of Bristol-Myers Squibb

Let's see what the charts and indicators look like.

The Real Money Post Industrial Average Gains More Ground in February

The Real Money Post Industrial Average Gains More Ground in February

However, the RMPIA did not see as much improvement last month as some other market indices.

5 Attractive Ways to Invest in Oncology

5 Attractive Ways to Invest in Oncology

Experts offer their top stock ideas in oncology detection and treatment.

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.

The Real Money Post Industrial Average Continues to Soar

The Real Money Post Industrial Average Continues to Soar

The RMPIA rose 10.5% during the first half of the current quarter.

Real Money Post-Industrial Average Shines in January, Outperforming S&P 500

Real Money Post-Industrial Average Shines in January, Outperforming S&P 500

RMPIA soared 9.9% for the month, led by 11 double-digit gainers.

Celgene Downgraded to Hold at Jefferies

The Human Response Factor, Fed Moves, China Talks, MSFT Results: Market Recon

The Human Response Factor, Fed Moves, China Talks, MSFT Results: Market Recon

Many see the Fed as done for the year. Never assume. Read the words as they are written.

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

These themes are working despite the turmoil in Washington and slowing global growth.

These 2 Biotech Stocks Seem Significantly Undervalued

These 2 Biotech Stocks Seem Significantly Undervalued

I would add to them on any significant dips in the market.

Real Money Post-Industrial Average Records 7% Gain So Far in 2019

Real Money Post-Industrial Average Records 7% Gain So Far in 2019

The RMPIA is once again outpacing the S&P 500, Dow Jones Industrial Average and the Nasdaq Composite Index.

Jim Cramer: There's a Ton More Deals in the Pipe

Jim Cramer: There's a Ton More Deals in the Pipe

Deals that simply were unworkable four months ago because of price are now being done with alacrity.

Goldman's Gold Standard in M&A Bolsters Outlook for 2019

Goldman's Gold Standard in M&A Bolsters Outlook for 2019

Goldman is top of the heap for takeovers.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Try This Allergan Two-Week Setup

Try This Allergan Two-Week Setup

The company is set to report earnings on Jan. 29, so traders have a couple of weeks to watch the action.

Some Early 2019 Market Observations

Some Early 2019 Market Observations

I would not be surprised if we see a bout of profit-taking in the near future given the sharpness of the recent rebound.

This Market May Just Be in an Uptrend: Market Recon

This Market May Just Be in an Uptrend: Market Recon

This is the kind of reversal that happens in a bull market.

2 Small-Caps That Should Continue to Stage Comebacks in 2019

2 Small-Caps That Should Continue to Stage Comebacks in 2019

Beaten-down Entercom Communications and Dynavax Technologies are off to good starts this year and should continue to improve.

Real Money Post Industrial Average Outperformed the Market in 2018

Real Money Post Industrial Average Outperformed the Market in 2018

The RMPIA index was up for the year, while the S&P 500, DJIA, Russell 2000 and Nasdaq all finished 2018 in the red.

My 2 Top Stock Picks for 2019

My 2 Top Stock Picks for 2019

It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.

Let's See If Friday's Sunshine Was More Than a Break in the Clouds: Market Recon

Let's See If Friday's Sunshine Was More Than a Break in the Clouds: Market Recon

It's likely that investors will be closely watching the U.S.-China trade talks to see if the skies brighten longer term.

Jim Cramer: These Pharma Deals Are Game Changers

Jim Cramer: These Pharma Deals Are Game Changers

Pharma companies that have cash are looking at what has happened to this stock market and buying.